Dagher Ibrahim B. 4

What Happened
Ibrahim B. Dagher, a director of BrainStorm Cell Therapeutics, was granted a derivative award on 2026-02-26: options covering 225,000 shares with an exercise price of $0.70 per share (total grant value noted as $157,500). This was an award/grant of stock options (transaction code A), not an open‑market purchase or sale.

Key Details

• Transaction date: 2026-02-26; Filing date (Form 4): 2026-05-20 (appears late; Form 4s are normally due within 2 business days).
• Award: 225,000 options, exercise price $0.70; reported value $157,500 (derivative instrument).
• Plan: Options granted under the Issuer’s 2014 Stock Incentive Plan (footnote F1).
• Vesting: 50% vested on grant date; remaining 50% vests six months after grant, contingent on continued service (footnote F2).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Transaction type: Award/grant of options (A); not an exercise or sale.

Context
This filing documents a grant of stock options (a derivative right to buy shares in the future) rather than an immediate purchase or sale of shares. The options vest in two installments (half at grant, half after six months if the director remains with the company). The reported Form 4 was filed on 2026-05-20 for a 2026-02-26 grant, which is later than the typical two-business-day filing window.